Trial intelligence / Profile preview

Post-marketing safety and effectiveness study of Daclatasvir in chronic hepatitis C in China

CTR20181234Phase 4Terminated

Sponsor
Bristol Myers Squibb
Start
Sep 2018
Modality
Small Molecules
Countries
1
01

Overview

A Phase 4 trial of daclatasvir in hepatitis C virus infection, sponsored by Bristol Myers Squibb. Started Sep 2018; status: terminated.

02

Drugs

daclatasvir
03

Conditions

hepatitis C virus infection

Beyond the preview

Go deeper on CTR20181234.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20181234.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call